NASDAQ:EYEG - EyeGate Pharma Stock Price, Price Target & More

$0.4901 0.00 (0.00 %)
(As of 04/20/2018 02:34 AM ET)
Previous Close$0.4901
Today's Range$0.45 - $0.4990
52-Week Range$0.29 - $2.43
Volume2.36 million shs
Average Volume913,596 shs
Market Capitalization$8.65 million
P/E Ratio-0.48
Dividend YieldN/A
Beta3.58

About EyeGate Pharma (NASDAQ:EYEG)

EyeGate Pharma logoEyeGate Pharma is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its products include EGP-437 and EyeGate II Delivery System. EGP-437 treat non-infectious anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris or ciliary body. The EyeGate II Delivery System delivers drugs non-invasively and quickly into the ocular tissues through the use of iontophoresis, which can accelerate the onset of action, dramatically reduce treatment frequency versus eye drops and sustain therapeutic effect. The company was founded in 1998 and is headquartered in Waltham, MA.

Receive EYEG News and Ratings via Email

Sign-up to receive the latest news and ratings for EYEG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EYEG
CUSIPN/A
Phone781-788-9043

Debt

Debt-to-Equity RatioN/A
Current Ratio0.57%
Quick Ratio0.57%

Price-To-Earnings

Trailing P/E Ratio-0.48
Forward P/E Ratio-0.71
P/E GrowthN/A

Sales & Book Value

Annual Sales$410,000.00
Price / Sales21.11
Cash FlowN/A
Price / CashN/A
Book Value($0.11) per share
Price / Book-4.46

Profitability

EPS (Most Recent Fiscal Year)($1.02)
Net Income$-13,210,000.00
Net Margins-2,480.28%
Return on Equity-2,683.87%
Return on Assets-96.01%

Miscellaneous

Employees17
Outstanding Shares17,660,000

How to Become a New Pot Stock Millionaire

EyeGate Pharma (NASDAQ:EYEG) Frequently Asked Questions

What is EyeGate Pharma's stock symbol?

EyeGate Pharma trades on the NASDAQ under the ticker symbol "EYEG."

How were EyeGate Pharma's earnings last quarter?

EyeGate Pharma (NASDAQ:EYEG) announced its quarterly earnings results on Friday, March, 2nd. The specialty pharmaceutical company reported ($0.21) EPS for the quarter, beating the Zacks' consensus estimate of ($0.25) by $0.04. EyeGate Pharma had a negative return on equity of 2,683.87% and a negative net margin of 2,480.28%. View EyeGate Pharma's Earnings History.

When is EyeGate Pharma's next earnings date?

EyeGate Pharma is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for EyeGate Pharma.

What price target have analysts set for EYEG?

2 brokers have issued 12 month target prices for EyeGate Pharma's stock. Their predictions range from $3.00 to $3.00. On average, they expect EyeGate Pharma's share price to reach $3.00 in the next twelve months. View Analyst Ratings for EyeGate Pharma.

Who are some of EyeGate Pharma's key competitors?

Who are EyeGate Pharma's key executives?

EyeGate Pharma's management team includes the folowing people:
  • Stephen From, President, Chief Executive Officer & Director
  • Sarah M. Romano, Chief Financial & Accounting Officer
  • Lisa Brandano, Vice President-Clinical Operations
  • Barbara Wirostko, Chief Medical Officer
  • Michael P. Manzo, Vice President-Engineering

When did EyeGate Pharma IPO?

(EYEG) raised $5 million in an initial public offering on Friday, February 13th 2015. The company issued 800,000 shares at $6.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO.

Has EyeGate Pharma been receiving favorable news coverage?

News stories about EYEG stock have trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. EyeGate Pharma earned a news sentiment score of 0.09 on Accern's scale. They also assigned news coverage about the specialty pharmaceutical company an impact score of 46.01 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are EyeGate Pharma's major shareholders?

EyeGate Pharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include ARMISTICE CAPITAL, LLC (4.99%). Company insiders that own EyeGate Pharma stock include Armistice Capital Master Fund, Morton Goldberg, Sarah Romano, Stephen From and Ventech Capital Ii. View Institutional Ownership Trends for EyeGate Pharma.

How do I buy shares of EyeGate Pharma?

Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is EyeGate Pharma's stock price today?

One share of EYEG stock can currently be purchased for approximately $0.4901.

How big of a company is EyeGate Pharma?

EyeGate Pharma has a market capitalization of $8.65 million and generates $410,000.00 in revenue each year. The specialty pharmaceutical company earns $-13,210,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. EyeGate Pharma employs 17 workers across the globe.

How can I contact EyeGate Pharma?

EyeGate Pharma's mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at 781-788-9043.


MarketBeat Community Rating for EyeGate Pharma (EYEG)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  162 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  239
MarketBeat's community ratings are surveys of what our community members think about EyeGate Pharma and other stocks. Vote "Outperform" if you believe EYEG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYEG will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

EyeGate Pharma (NASDAQ:EYEG) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for EyeGate Pharma in the last 12 months. Their average twelve-month price target is $3.00, suggesting that the stock has a possible upside of 512.12%. The high price target for EYEG is $3.00 and the low price target for EYEG is $3.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.00$3.00$5.00$7.3333
Price Target Upside: 512.12% upside424.75% upside309.84% upside543.27% upside

EyeGate Pharma (NASDAQ:EYEG) Consensus Price Target History

Price Target History for EyeGate Pharma (NASDAQ:EYEG)

EyeGate Pharma (NASDAQ:EYEG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/11/2018HC WainwrightSet Price TargetBuy$3.00HighView Rating Details
5/19/2017Noble FinancialReiterated RatingBuyLowView Rating Details
12/6/2016Chardan CapitalReiterated RatingBuy$6.00N/AView Rating Details
12/1/2016Rodman & RenshawReiterated RatingBuy$10.00N/AView Rating Details
6/28/2016Maxim GroupReiterated RatingHoldN/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

EyeGate Pharma (NASDAQ:EYEG) Earnings History and Estimates Chart

Earnings by Quarter for EyeGate Pharma (NASDAQ:EYEG)

EyeGate Pharma (NASDAQ:EYEG) Earnings Estimates

2018 EPS Consensus Estimate: ($0.71)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.23)($0.23)($0.23)
Q2 20181($0.21)($0.21)($0.21)
Q3 20181($0.15)($0.15)($0.15)
Q4 20181($0.12)($0.12)($0.12)

EyeGate Pharma (NASDAQ EYEG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.24)N/AView Earnings Details
3/2/2018Q4 2017($0.25)($0.21)ViewN/AView Earnings Details
11/14/2017Q3 2017($0.24)($0.24)$0.16 million$0.08 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.19)($0.28)$1.52 million$0.15 millionViewN/AView Earnings Details
5/8/20173/31/2017($0.39)($0.39)$0.22 million$0.19 millionViewN/AView Earnings Details
2/23/2017Q4 2016($0.44)($0.38)$0.20 million$0.16 millionViewN/AView Earnings Details
11/1/2016Q3 2016($0.46)($0.36)$0.20 million$0.27 millionViewN/AView Earnings Details
8/10/2016Q2 2016($0.31)($0.46)$0.24 millionViewN/AView Earnings Details
5/13/2016Q1 2016($0.25)($0.31)ViewN/AView Earnings Details
3/30/2016Q4 2015($0.20)($0.24)ViewN/AView Earnings Details
11/12/2015Q3 2015($0.19)ViewN/AView Earnings Details
8/12/2015Q2 2015($0.24)ViewN/AView Earnings Details
5/15/2015Q1 2015($3.23)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

EyeGate Pharma (NASDAQ:EYEG) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

EyeGate Pharma (NASDAQ EYEG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 24.60%
Institutional Ownership Percentage: 10.47%
Insider Trading History for EyeGate Pharma (NASDAQ:EYEG)
Insider Trading History for EyeGate Pharma (NASDAQ:EYEG)

EyeGate Pharma (NASDAQ EYEG) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/17/2018Armistice Capital Master FundMajor ShareholderBuy10,479,970$0.36$3,772,789.20View SEC Filing  
8/15/2017Sarah RomanoCFOBuy10,000$1.00$10,000.0032,500View SEC Filing  
8/10/2017Stephen FromInsiderBuy12,500$1.03$12,875.00272,465View SEC Filing  
3/6/2017Morton GoldbergDirectorSell8,919$3.00$26,757.009,441View SEC Filing  
9/15/2016Stephen FromInsiderBuy15,000$1.49$22,350.00139,965View SEC Filing  
6/15/2016Morton GoldbergDirectorSell15,000$3.16$47,400.0017,277View SEC Filing  
6/10/2016Ventech Capital IiMajor ShareholderSell28,600$3.04$86,944.001,608,973View SEC Filing  
6/8/2016Ventech Capital IiMajor ShareholderSell29,400$3.25$95,550.001,641,540View SEC Filing  
6/7/2016Morton GoldbergDirectorSell10,939$3.31$36,208.0943,216View SEC Filing  
2/19/2015(Innoven Partenaires S.A. IpsaMajor ShareholderBuy366,667$6.00$2,200,002.00View SEC Filing  
2/19/2015Paul G ChaneyDirectorBuy8,333$6.00$49,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

EyeGate Pharma (NASDAQ EYEG) News Headlines

Source:
DateHeadline
EyeGate Pharma (EYEG) Major Shareholder Armistice Capital Master Fund Buys 10,479,970 SharesEyeGate Pharma (EYEG) Major Shareholder Armistice Capital Master Fund Buys 10,479,970 Shares
www.americanbankingnews.com - April 18 at 10:21 AM
Your Daily Pharma Scoop: Intercepts OCA, MediciNova In NASH, Pulse Biosciences DataYour Daily Pharma Scoop: Intercept's OCA, MediciNova In NASH, Pulse Biosciences Data
seekingalpha.com - April 16 at 8:16 AM
EyeGate Pharma (EYEG) Given a $6.00 Price Target by HC Wainwright AnalystsEyeGate Pharma (EYEG) Given a $6.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 14 at 10:05 AM
Mid-Afternoon Market Update: Skyline Rises After Q3 Results; EyeGate Pharmaceuticals Shares PlungeMid-Afternoon Market Update: Skyline Rises After Q3 Results; EyeGate Pharmaceuticals Shares Plunge
feeds.benzinga.com - April 13 at 3:36 PM
EyeGate Pharma to Post Q2 2018 Earnings of ($0.21) Per Share, Zacks Investment Research Forecasts (EYEG)EyeGate Pharma to Post Q2 2018 Earnings of ($0.21) Per Share, Zacks Investment Research Forecasts (EYEG)
www.americanbankingnews.com - April 13 at 8:47 AM
Eyegate Pharma (EYEG) Announces $11.25 Million Public Offering of Common Stock, WarrantsEyegate Pharma (EYEG) Announces $11.25 Million Public Offering of Common Stock, Warrants
www.streetinsider.com - April 13 at 8:19 AM
EyeGate Pharma prices $11.25M equity offering; shares down 24% premarketEyeGate Pharma prices $11.25M equity offering; shares down 24% premarket
seekingalpha.com - April 13 at 8:19 AM
Eyegate Pharma (EYEG) Secures New Patent for Iontophoretic Contact Lens TechnologyEyegate Pharma (EYEG) Secures New Patent for Iontophoretic Contact Lens Technology
www.streetinsider.com - April 12 at 5:38 PM
Mid-Day Market Update: Analogic Falls Following Acquisition News; EyeGate Pharmaceuticals Shares GainMid-Day Market Update: Analogic Falls Following Acquisition News; EyeGate Pharmaceuticals Shares Gain
www.benzinga.com - April 11 at 5:31 PM
EyeGate nabs U.S. patent covering iontophoretic contact lens; shares up 29%EyeGate nabs U.S. patent covering iontophoretic contact lens; shares up 29%
seekingalpha.com - April 11 at 5:31 PM
EyeGate Issued New Patent for Iontophoretic Contact Lens TechnologyEyeGate Issued New Patent for Iontophoretic Contact Lens Technology
finance.yahoo.com - April 11 at 5:31 PM
Eyegate Pharma (EYEG) Announces FDA Feedback on IDE Amendment for Second Pilot Study of Ocular Bandage GelEyegate Pharma (EYEG) Announces FDA Feedback on IDE Amendment for Second Pilot Study of Ocular Bandage Gel
www.streetinsider.com - April 10 at 8:27 AM
Your Daily Pharma Scoop: Acadia Sell-Off, Therapix Soars On Results, Menlo SetbackYour Daily Pharma Scoop: Acadia Sell-Off, Therapix Soars On Results, Menlo Setback
seekingalpha.com - April 10 at 8:27 AM
EyeGate sees Q3 start for second pilot study of lead candidate EyeGate OBG; shares slip 6% premarketEyeGate sees Q3 start for second pilot study of lead candidate EyeGate OBG; shares slip 6% premarket
seekingalpha.com - April 9 at 5:22 PM
BRIEF-EyeGate Gets Milestone Payment For Confirmatory Study Of Eye Inflammation TreatmentBRIEF-EyeGate Gets Milestone Payment For Confirmatory Study Of Eye Inflammation Treatment
www.reuters.com - April 6 at 5:41 PM
EyeGate Pharma completes enrollment in late-stage study of EGP-437, milestone earned; shares up 18% premarketEyeGate Pharma completes enrollment in late-stage study of EGP-437, milestone earned; shares up 18% premarket
seekingalpha.com - April 6 at 5:41 PM
Head-To-Head Contrast: EyeGate Pharma (EYEG) versus Regulus Therapeutics (RGLS)Head-To-Head Contrast: EyeGate Pharma (EYEG) versus Regulus Therapeutics (RGLS)
www.americanbankingnews.com - April 2 at 1:16 PM
EyeGate Pharma (EYEG) Given "Buy" Rating at HC WainwrightEyeGate Pharma (EYEG) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - March 31 at 5:28 PM
Eyegate Pharmaceuticals (EYEG) Raised to "Sell" at ValuEngineEyegate Pharmaceuticals (EYEG) Raised to "Sell" at ValuEngine
www.americanbankingnews.com - March 25 at 6:25 PM
BRIEF-Eyegate Pharmaceuticals Files For Potential Mixed Shelf Of Up To $20 MlnBRIEF-Eyegate Pharmaceuticals Files For Potential Mixed Shelf Of Up To $20 Mln
www.reuters.com - March 23 at 5:42 PM
Eyegate Pharmaceuticals (EYEG) Given a $3.00 Price Target at HC WainwrightEyegate Pharmaceuticals (EYEG) Given a $3.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 18 at 9:22 PM
EyeGate Pharma To Participate At The 30TH Annual ROTH Conference - GlobeNewswire (press release)EyeGate Pharma To Participate At The 30TH Annual ROTH Conference - GlobeNewswire (press release)
globenewswire.com - March 10 at 8:22 AM
EyeGate Pharma To Participate At The 30TH Annual ROTH ConferenceEyeGate Pharma To Participate At The 30TH Annual ROTH Conference
finance.yahoo.com - March 9 at 6:50 PM
EyeGate Pharma Submits Investigational Device Exemption ... - NasdaqEyeGate Pharma Submits Investigational Device Exemption ... - Nasdaq
www.nasdaq.com - March 9 at 8:20 AM
Analysts Set Expectations for Eyegate Pharmaceuticals Incs Q1 2018 Earnings (EYEG)Analysts Set Expectations for Eyegate Pharmaceuticals Inc's Q1 2018 Earnings (EYEG)
www.americanbankingnews.com - March 9 at 7:54 AM
EyeGate Pharma Submits Investigational Device Exemption ... - GlobeNewswire (press release)EyeGate Pharma Submits Investigational Device Exemption ... - GlobeNewswire (press release)
globenewswire.com - March 8 at 6:44 PM
Eyegate Pharma (EYEG) Submits Investigational Device Exemption ... - StreetInsider.comEyegate Pharma (EYEG) Submits Investigational Device Exemption ... - StreetInsider.com
www.streetinsider.com - March 8 at 6:44 PM
EyeGate Pharmaceuticals Inc (NASDAQ:EYEG): Poised For Long-Term Success?EyeGate Pharmaceuticals Inc (NASDAQ:EYEG): Poised For Long-Term Success?
finance.yahoo.com - March 8 at 6:44 PM
FY2020 Earnings Estimate for Eyegate Pharmaceuticals Inc Issued By Zacks Investment Research (EYEG)FY2020 Earnings Estimate for Eyegate Pharmaceuticals Inc Issued By Zacks Investment Research (EYEG)
www.americanbankingnews.com - March 8 at 2:32 PM
HC Wainwright Analysts Give Eyegate Pharmaceuticals (EYEG) a $3.00 Price TargetHC Wainwright Analysts Give Eyegate Pharmaceuticals (EYEG) a $3.00 Price Target
www.americanbankingnews.com - March 5 at 2:58 PM
EyeGate Pharmaceuticals Reports Full-Year 2017 Financial Results ... - GlobeNewswire (press release)EyeGate Pharmaceuticals Reports Full-Year 2017 Financial Results ... - GlobeNewswire (press release)
globenewswire.com - March 3 at 8:16 AM
EyeGate Pharmaceuticals Reports Full-Year 2017 Financial Results and Provides Business UpdateEyeGate Pharmaceuticals Reports Full-Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 2 at 6:10 PM
FY2019 EPS Estimates for Eyegate Pharmaceuticals Inc (EYEG) Lowered by Zacks Investment ResearchFY2019 EPS Estimates for Eyegate Pharmaceuticals Inc (EYEG) Lowered by Zacks Investment Research
www.americanbankingnews.com - February 23 at 3:52 PM
EYEG: Cataract Surgery Phase II Topline Data: Efficacy Signal Despite Miss to Primary EndpointEYEG: Cataract Surgery Phase II Topline Data: Efficacy Signal Despite Miss to Primary Endpoint
finance.yahoo.com - February 22 at 5:37 PM
Eyegate Pharmaceuticals (EYEG) to Release Earnings on WednesdayEyegate Pharmaceuticals (EYEG) to Release Earnings on Wednesday
www.americanbankingnews.com - February 14 at 2:20 AM
Head-To-Head Review: Eyegate Pharmaceuticals (EYEG) versus Lannett (LCI)Head-To-Head Review: Eyegate Pharmaceuticals (EYEG) versus Lannett (LCI)
www.americanbankingnews.com - February 12 at 3:36 AM
EyeGate to Present at the 2018 BIO CEO & Investor ConferenceEyeGate to Present at the 2018 BIO CEO & Investor Conference
finance.yahoo.com - February 7 at 9:34 AM
Eyegate Pharmaceuticals (EYEG) Earns "Buy" Rating from HC WainwrightEyegate Pharmaceuticals (EYEG) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - February 7 at 12:40 AM
Mid-Day Market Update: Dow Falls Over 250 Points; Enphase Energy Shares Spike HigherMid-Day Market Update: Dow Falls Over 250 Points; Enphase Energy Shares Spike Higher
www.benzinga.com - February 5 at 3:41 PM
What Spooked Eyegate Pharmaceuticals Inc Investors TodayWhat Spooked Eyegate Pharmaceuticals Inc Investors Today
finance.yahoo.com - February 5 at 3:41 PM
What Spooked Eyegate Pharmaceuticals Inc Investors TodayWhat Spooked Eyegate Pharmaceuticals Inc Investors Today
finance.yahoo.com - February 5 at 3:41 PM
Eyegate Pharma (EYEG) Reports Top-Line Results for Phase 2b Trial of EGP-437 in Cataract SurgeryEyegate Pharma (EYEG) Reports Top-Line Results for Phase 2b Trial of EGP-437 in Cataract Surgery
www.streetinsider.com - February 5 at 9:34 AM
EyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract SurgeryEyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract Surgery
finance.yahoo.com - February 5 at 9:34 AM
Reviewing Eyegate Pharmaceuticals (EYEG) & Lannett (LCI)Reviewing Eyegate Pharmaceuticals (EYEG) & Lannett (LCI)
www.americanbankingnews.com - February 1 at 11:33 AM
Eyegate Pharmaceuticals Inc (EYEG) Expected to Announce Earnings of -$0.25 Per ShareEyegate Pharmaceuticals Inc (EYEG) Expected to Announce Earnings of -$0.25 Per Share
www.americanbankingnews.com - January 26 at 7:12 PM
Should You Worry About Eyegate Pharmaceuticals Inc’s (NASDAQ:EYEG) CEO Pay Check?Should You Worry About Eyegate Pharmaceuticals Inc’s (NASDAQ:EYEG) CEO Pay Check?
finance.yahoo.com - January 20 at 9:29 AM
Eyegate Pharma (EYEG) Announces Promotion of Sarah Romano to CFO PositionEyegate Pharma (EYEG) Announces Promotion of Sarah Romano to CFO Position
www.streetinsider.com - January 4 at 5:25 PM
Eyegate Pharma (EYEG) Announces Promotion of Sarah Romano to CFO Position - StreetInsider.comEyegate Pharma (EYEG) Announces Promotion of Sarah Romano to CFO Position - StreetInsider.com
www.streetinsider.com - January 4 at 9:23 AM
EyeGate Promotes Sarah Romano to Chief Financial OfficerEyeGate Promotes Sarah Romano to Chief Financial Officer
finance.yahoo.com - January 4 at 9:23 AM
With A -14.24% Earnings Drop Lately, Did Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) Underperform Its Industry?With A -14.24% Earnings Drop Lately, Did Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) Underperform Its Industry?
finance.yahoo.com - January 2 at 6:51 PM

SEC Filings

EyeGate Pharma (NASDAQ:EYEG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

EyeGate Pharma (NASDAQ EYEG) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.